Press release
Opioid Use Disorder Pipeline Drugs Report 2025: Comprehensive Insights into Emerging Therapies, Clinical Trials, and Market Opportunities Shaping SMA Treatment Landscape
Curious about the latest updates in the Opioid Use Disorder Pipeline? Click here to explore the therapies and trials making headlines @ Opioid Use Disorder Pipeline Outlook Report [https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Opioid Use Disorder Pipeline Report
* On 18 September 2025, Indivior Inc. announced a study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE Registered ) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE Registered ). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
* DelveInsight's Opioid Use Disorder Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Opioid Use Disorder treatment.
* The leading Opioid Use Disorder Companies, such as GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma , and others.
* Promising Opioid Use Disorder Therapies such as XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM203,8, and others.
Want to know which companies are leading innovation in Opioid Use Disorder? Dive into the full pipeline insights @ Opioid Use Disorder Clinical Trials Assessment [https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Opioid Use Disorder Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Opioid Use Disorder Pipeline Report also highlights the unmet needs with respect to the Opioid Use Disorder.
Opioid Use Disorder Overview
Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Although opioids reduce the perception of pain but chronic use of opioids can cause distress and impairment. Opioid Related Disorder includes overpowering desire to use opioids, dependence, increased opioid tolerance, and addictions which represents the most severe form of the disorders. When discontinued, the individual suffers from withdrawal syndrome.
Opioid Use Disorder Emerging Drugs Profile
* ASP8062: Astellas Pharma
Astellas Pharma's lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active -amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid Related Disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.
* OPNT-003 (Intranasal Nalmefene): Opiant Pharmaceuticals
Opiant Pharmaceuticals "breakthrough" drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.
If you're tracking ongoing Opioid Use Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Opioid Use Disorder Treatment Drugs [https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Opioid Use Disorder Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Opioid Use Disorder with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Use Disorder Treatment.
* Opioid Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Opioid Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Use Disorder market.
Opioid Use Disorder Companies
GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma , and others
Opioid Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Subcutaneous
* Intravenous
* Oral
* Intramuscular
* Molecule Type
Opioid Use Disorder Products have been categorized under various Molecule types such as
* Small molecules
* Natural metabolites
* Monoclonal antibodies
* Product Type
From emerging drug candidates to competitive intelligence, the Opioid Use Disorder Pipeline Report covers it all - check it out now @ Opioid Use Disorder Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Opioid Use Disorder Pipeline Report
* Coverage- Global
* Opioid Use Disorder Companies- GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma , and others.
* Promising Opioid Use Disorder Therapies- XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM2038 and others.
* Opioid Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Opioid Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Opioid Use Disorder Treatment landscape in this detailed analysis @ Opioid Use Disorder Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Opioid Related Disorder: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Opioid Related Disorder - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Opioid Related Disorder Collaboration Deals
* Mid Stage Products (Phase II)
* ASP8062: Astellas Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* OPNT-003: Opiant Pharmaceuticals
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Opioid Related Disorder Key Companies
* Opioid Related Disorder Key Products
* Opioid Related Disorder- Unmet Needs
* Opioid Related Disorder- Market Drivers and Barriers
* Opioid Related Disorder- Future Perspectives and Conclusion
* Opioid Related Disorder Analyst Views
* Opioid Related Disorder Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=opioid-use-disorder-pipeline-drugs-report-2025-comprehensive-insights-into-emerging-therapies-clinical-trials-and-market-opportunities-shaping-sma-treatment-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/opioid-related-disorder-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid Use Disorder Pipeline Drugs Report 2025: Comprehensive Insights into Emerging Therapies, Clinical Trials, and Market Opportunities Shaping SMA Treatment Landscape here
News-ID: 4196698 • Views: …
More Releases from ABNewswire
Treatment-Resistant Hypertension market is projected to grow at a CAGR of 6.30% …
Treatment-Resistant Hypertension market size in the 7MM was valued at approximately USD 6,958 million in 2025. Over the forecast period from 2025 to 2034.
Therapies for Treatment-Resistant Hypertension, including Baxdrostat (CIN-107), Lorundrostat (MLS-101), TRYVIO/JERAYGO (aprocitentan), and others, are anticipated to drive growth in the Treatment-Resistant Hypertension market in the coming years.
DelveInsight has released a comprehensive report titled "Treatment-Resistant Hypertension - Market Insights, Epidemiology, and Market Forecast-2034," providing detailed insights into the…
Periodontal Disease Market: Insights into Epidemiology, Available Therapies, and …
According to the secondary analysis, cross-sectional data from the US reveal a substantial burden of periodontal conditions, with approximately 50% of the adult population currently affected by gingivitis and up to 80% having experienced some form of periodontal disease over their lifetime. These figures highlight the widespread nature of periodontal health issues and underscore the need for improved preventive strategies and public awareness.
Emerging therapies for Periodontal Disease, including VAX PG,…
Single Ventricle Heart Disease Market: Insights into Epidemiology, Available The …
To drive the Single Ventricle Heart Disease Market in future years, several Single Ventricle Heart Disease Companies such as Mezzion Pharma, Metcela, and others are developing their assets in the mid-late stage of development. The anticipated approval of Single Ventricle Heart Disease therapies, including Udenafil and JRM-001, among others, during the forecast period (2024-2034), is expected to further drive the market growth.
Emerging therapies for Single Ventricle Heart Disease, including Udenafil,…
Acute Myeloid Leukemia Pipeline Drugs Report 2025 by DelveInsight: Examining Dru …
DelveInsight's "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
More Releases for Opioid
Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting…
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Opioid Use Disorder (OUD) Market Size By 2025?
The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound…
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain…
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market?
The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance…
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the…
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana.
Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622
Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal…
